Octagon Capital Advisors’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-382,000
| Closed | -$5.86M | – | 43 |
|
|
2023
Q1 | $5.86M | Buy |
382,000
+57,371
| +18% | +$881K | 0.84% | 23 |
|
|
2022
Q4 | $7.2M | Sell |
324,629
-55,000
| -14% | -$1.22M | 1.12% | 19 |
|
|
2022
Q3 | $6.2M | Buy |
379,629
+57,988
| +18% | +$947K | 1.07% | 22 |
|
|
2022
Q2 | $4.67M | Hold |
321,641
| – | – | 1.25% | 12 |
|
|
2022
Q1 | $5.94M | Sell |
321,641
-125,000
| -28% | -$2.31M | 1.28% | 18 |
|
|
2021
Q4 | $10.6M | Hold |
446,641
| – | – | 2.07% | 14 |
|
|
2021
Q3 | $11M | Hold |
446,641
| – | – | 2.71% | 12 |
|
|
2021
Q2 | $11M | Hold |
446,641
| – | – | 2.29% | 15 |
|
|
2021
Q1 | $9.74M | Buy |
446,641
+16,600
| +4% | +$362K | 3.67% | 11 |
|
|
2020
Q4 | $11M | Buy |
+430,041
| New | +$11M | 3.8% | 12 |
|